Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia. Moujalled DM, Brown FC, Chua CC, Dengler MA, et al. Blood 2022 Oct 11. pii: 486781. doi: 10.1182/blood.2022016090.

Read + Share

Amedeo Smart

Independent Medical Education

Moujalled DM, Brown FC, Chua CC, Dengler MA, et al. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia. Blood 2022 Oct 11. pii: 486781. doi: 10.1182/blood.2022016090.
PMID: 36219880